
Guidance for Industry Collection of Race and Ethnicity Data in Clinical Trials

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit comments to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (OC) Katherine Hollinger at (301)827-0350, (CDER) Nancy Derr at 301-594-5400, (CBER) Ilan Irony at 301-827-5378 or (CDRH) IDE Staff at (301)594-1190.

-

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)
Office of the Commissioner (OC)**

**January 2003
Procedural**

Guidance for Industry

Collection of Race and Ethnicity Data in Clinical Trials

*Office of Training and Communication
Division of Drug Information, HFD-240
Center for Drug Evaluation and Research
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857
(Tel) 301-827-4573
<http://www.fda.gov/cder/guidance/index.htm>*

or

*Office of Communication, Training and
Manufacturers Assistance, HFM-40
Center for Biologics Evaluation and Research
Food and Drug Administration
1401 Rockville Pike, Rockville, MD 20852-1448
<http://www.fda.gov/cber/guidelines.htm>
(Tel) Voice Information System at 800-835-4709 or 301-827-1800
*or**

*Center for Devices and Radiological Health (HFZ-220)
Food and Drug Administration
1350 Piccard Drive
Rockville, MD 20850-4307 U.S.A.
<http://www.fda.gov/cdrh/ggpmain.html>
Email: dsma@cdrh.fda.gov
Fax: 301.443.8818
(Tel) Manufacturers Assistance: 800.638.2041 or 301.443.6597*

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)
Office of the Commissioner (OC)**

**January 2003
Procedural**

TABLE OF CONTENTS

I. INTRODUCTION..... 1

II. BACKGROUND 2

A. Relevance of Population Subgroup Studies 3

B. FDA Decision to Recommend Use of the OMB Categories..... 4

III. COLLECTING RACE AND ETHNICITY DATA IN CLINICAL TRIALS..... 5

IV. CLINICAL TRIALS CONDUCTED OUTSIDE OF THE UNITED STATES 5

**APPENDIX 1: HISTORY OF FEDERAL EFFORTS IN DATA COLLECTION ON
RACE AND ETHNICITY AND OTHER SUBPOPULATIONS..... 7**

APPENDIX 2: REVISED DIRECTIVE 15 12

REFERENCES..... 16

BIBLIOGRAPHY 17

Contains Nonbinding Recommendations

Draft — Not for Implementation

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

Guidance for Industry¹ Collection of Race and Ethnicity Data in Clinical Trials

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

I. INTRODUCTION

This guidance recommends a standardized approach for collecting race and ethnicity information in clinical trials conducted in the United States and abroad for certain FDA regulated products. The standardized approach being recommended was developed by the Office of Management and Budget (OMB). The guidance explains the OMB categories and FDA's reasons for recommending the use of the OMB categories.²

This document provides guidance on the requirements set forth in the 1998 final rule on Investigational New Drug Applications and New Drug Applications³ (Demographic Rule). The Demographic Rule requires sponsors of new drug applications (NDAs) to include in their applications analyses of effectiveness and safety data for important demographic subgroups, including racial subgroups.⁴

Although the regulations governing medical devices do not include requirements for the collection of demographic data comparable to those for INDs and NDAs described above, for those cases in which race and ethnicity data are relevant to determining the safety and effectiveness of a device, FDA encourages sponsors to collect the data in accordance with the OMB information collection standards discussed in this guidance document. Sponsors are also

¹ This guidance has been developed by the Race and Ethnicity Working Group from the Office of the Commissioner, the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA). This guidance is an FDA Data Council initiative to recommend the standardized collection of health information in a regulatory environment.

² The Agency is developing a companion guidance that will make recommendations about how to analyze and report race and ethnicity data.

³ 63 FR 6854 (Feb. 11, 1998) (codified at 21 CFR 312.33(a)(2) and 21 CFR 314.50(d)(5)).

⁴ 21 CFR 314.50(d)(5)(vi)(a).

Contains Nonbinding Recommendations

Draft — Not for Implementation

34 encouraged to discuss any race or ethnicity issue with the appropriate review division within the
35 Office of Device Evaluation, Center for Devices and Radiological Health, when developing their
36 study protocols.

37
38 This guidance does not discuss increasing the number of studies in which subpopulations are
39 exposed to a product. The guidance also does not discuss increasing the total number of
40 participants or members of a subpopulation in clinical trials.

41
42 FDA's guidance documents, including this guidance, do not establish legally enforceable
43 responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should
44 be viewed only as recommendations, unless specific regulatory or statutory requirements are
45 cited. The use of the word *should* in Agency guidances means that something is suggested or
46 recommended, but not required.

47
48

49 II. BACKGROUND

50

51 FDA regulations require sponsors to present in certain marketing applications an analysis of data
52 according to demographic subgroups (age, gender, race), as well as an analysis of modifications
53 of dose or dosage intervals for specific subgroups (21 CFR 314.50 (d)(5)(vi)(a)).⁵

54

55 In 1997, OMB issued its revised recommendations for the collection and use of race and
56 ethnicity data by Federal agencies (Policy Directive 15).⁶ FDA now recommends the use of the
57 standardized OMB race and ethnicity categories for data collection in clinical trials for two
58 reasons. First, the use of the recommended OMB categories will help ensure consistency in
59 demographic subset analyses across studies used to support certain marketing applications to
60 FDA and across data collected by other government agencies (21 CFR §§ 312.120 and 314.106
61 (b); see also *E5 Guidance on Ethnic Factors in the Acceptability of Foreign Clinical Data*⁷).
62 Second, these categories may be useful in evaluating potential differences in the safety and
63 efficacy of pharmaceutical products among population subgroups. To assess potential subgroup
64 differences in a meaningful way, it is important to provide guidance on the use of uniform,
65 standard categories in data collection for racial and ethnic subgroups.

66

⁵ Under 21 CFR 314.101(d)(3), the Agency may refuse-to-file an NDA if there is an inadequate evaluation for safety and/or effectiveness of the population intended to use the drug, including pertinent subsets, such as gender, age, and racial subsets. See FDA Guidance to Industry *Refusal to File* July 1993.

⁶ Statistical Policy Directive No. 15, Race and Ethnic Standards for Federal Statistics and Administrative Reporting, 1997 (reprinted in Appendix 2). See also OMB guidance entitled *Implementation of the 1997 Standards for Federal Data on Race and Ethnicity* (2000).

⁷ This guidance was developed under the auspices of the International Conference of Harmonisation (ICH). Reprinted at 63 FR 31790 (June 10, 1999).

Contains Nonbinding Recommendations

Draft — Not for Implementation

A. Relevance of Population Subgroup Studies

The OMB stated that its race and ethnicity categories were nonanthropologic (in other words, not scientifically based) designations but, instead, were categories that described the sociocultural construct of our society. The Department of Health and Human Services (HHS) chose to adopt these standardized categories for its agencies that report statistics, as the categories are relevant to assessing various health related data, including public health surveillance and research. FDA believes that the use of the OMB categories will facilitate comparisons across clinical studies analyzed by the FDA and with data collected by other agencies. Collection of data using standard categories may enhance patient safety by helping the Agency evaluate potential differences in drug response among subpopulations and may help facilitate analyses seeking differences in response.

Some differences in response to medical products have already been observed in racially and ethnically distinct subgroups of the U.S. population. These differences may be attributable to intrinsic factors (e.g., genetic, clearance⁸), extrinsic factors (e.g., diet, environmental exposure, sociocultural issues), or interactions between these factors. For example, in the United States, Whites⁹ are more likely than persons of Asian and African heritage to have abnormally low levels of an important enzyme (CYP2D6) that metabolizes drugs belonging to a variety of therapeutic areas, such as antidepressants, antipsychotics, and beta blockers (Xie 2001). Additionally, after using some drugs in the psychotherapeutic class, slower enzyme metabolism (CYP2C19) has been observed in persons in the United States of Asian descent as compared to Whites and Blacks (Xie 2001). Other studies have shown that Blacks respond poorly to several classes of antihypertensive agents (beta blockers and angiotensin converting enzyme (ACE) inhibitors) (Exner 2001 and Yancy 2001). Racial differences in skin structure and physiology have been noted that can affect response to dermatologic and topically applied products (Taylor 2002). Clinical trials have demonstrated lower responses to interferon-alpha used in the treatment of hepatitis C among Blacks when compared to other racial subgroups (McHutchison 2000 and Reddy 1999).

Collecting race and ethnicity data using standardized categories will enhance the early identification of differences in physiological response among racial and ethnic subgroups during the evaluation of safety and effectiveness of FDA-regulated products.¹⁰ Furthermore, collection of this data using standardized categories will facilitate comparisons across studies analyzed by FDA and with data collected by other Federal agencies.

⁸ Clearance is a measure of drug or biologic elimination from the body.

⁹ The terms used in this guidance to describe the various racial and ethnic groups are those used by OMB.

¹⁰ The importance of understanding population subgroup differences for effective risk management is discussed in greater detail in various reports, the published scientific literature, and Agency guidance documents and regulations (see the bibliography for a listing of relevant documents).

Contains Nonbinding Recommendations

Draft — Not for Implementation

B. FDA Decision to Recommend Use of the OMB Categories

103
104
105 Although the FDA has long requested race and ethnicity data on subjects in certain clinical trials,
106 the Agency has not made explicit recommendations on the categories to use when collecting and
107 reporting the data. In 1998, the Agency issued the Demographic Rule, which reflected the
108 growing recognition within the Agency and the health community that (1) different subgroups of
109 the population may respond differently to a specific drug product, and (2) although the effort
110 should be made to look for differences in effectiveness and adverse reactions among such
111 subgroups, that effort is not being made consistently.¹¹ In the Demographic Rule, the Agency
112 discussed the importance of collecting data in clinical trials (and of analyzing and presenting
113 those data in applications to the Agency) on population subgroups organized by gender, race,
114 age, and other relevant subgroups. The Agency recommended that sponsors ask subjects in
115 certain clinical trials to identify their racial group and, if desired, to use the OMB categories
116 when collecting race and ethnicity data.¹²

117
118 During the past two decades, efforts have been under way in a number of Federal organizations
119 to collect race and ethnicity data in Federal programs in a standardized way. (See Appendix 1
120 for a summary of those efforts). In 1997, HHS issued a statement entitled *Policy Statement on*
121 *Inclusion of Race and Ethnicity in DHHS Data Collection Activities*. In this policy statement,
122 HHS adopted the revised OMB categories for including race and ethnicity in HHS-funded and -
123 sponsored data collection and reporting systems. The HHS policy states that the categories
124 described in the revised OMB Directive 15 and its future revisions should be used when
125 collecting and reporting data in HHS data systems or reporting HHS-funded statistics.

126
127 The collection of standardized race and ethnicity data across HHS improves the quality and
128 consistency of reported health statistics. To be consistent with HHS policy and to facilitate and
129 enhance data consistency and comparability, FDA has decided to recommend the OMB
130 Directive 15 categories be used for the collection of race and ethnicity data in clinical trials.¹³
131 The Agency recommends that sponsors use the categories as outlined in this guidance when
132 collecting race and ethnicity data in clinical studies for FDA-regulated products conducted in
133 United States and abroad. More detailed race and ethnicity data can be collected when
134 appropriate to the study or locale, but we recommend that the OMB categories be identified for
135 all clinical trial participants when submitting such data to the Agency.

¹¹ 63 FR 6855 (1998).

¹² In the preamble to the final rule, FDA stated that it did not believe it was necessary to define specific racial categories in the rule itself because drug sponsors have been successful in identifying the relevant racial categories to examine safety and efficacy profiles of drugs (63 FR 6859). However, the FDA now believes that using uniform categories will enhance the consistency and comparability of data across studies submitted in marketing applications and across other government reported statistics.

¹³ OMB directed these activities to begin by January 1, 2003, in all Federal programs, including HHS. Although FDA sought and received a variance from OMB exempting the Agency from reporting data using the Directive 15 categories in the past, FDA now recommends the use of the categories to enhance data consistency.

Contains Nonbinding Recommendations

Draft — Not for Implementation

138 III. COLLECTING RACE AND ETHNICITY DATA IN CLINICAL TRIALS

139
140 The Agency recommends sponsors collect race and ethnicity data for clinical study participants
141 as specified in the OMB Directive and its revisions. However, the recommendations in this
142 section reflect the Agency's interest in more consistency in data collection. The Agency
143 recommends the use of a two-question format, and to have trial participants self-report their
144 racial and ethnic category to enhance consistency in the collection of the reported information.
145 Based on the current OMB Directive, the Agency provides the following recommendations for
146 the collection of the data:

- 147
- 148 1. We recommend using the two-question format for requesting race and ethnicity
149 information, with the ethnicity question preceding the question about race.
150
 - 151 2. We recommend that study participants self-report race and ethnicity information
152 whenever feasible, and individuals be permitted to designate a multiracial identity. When
153 the collection of self-reported designations is infeasible (e.g., because of the subject's
154 inability to respond), we recommend the information be requested from a first-degree
155 relative or other knowledgeable source.
156
 - 157 3. For ethnicity, we recommend the following minimum choices be offered:
158
 - Hispanic or Latino
 - Not Hispanic or Latino
159
 - 160 4. When race and ethnicity information is collected separately, we recommend the
161 following minimum choices be offered for race:
162
 - American Indian or Alaska Native
 - Asian
 - Black or African American
 - Native Hawaiian or Other Pacific Islander
 - White
163
 - 164 5. In certain situations, as recommended in OMB Directive 15, more detailed race and
165 ethnicity information may be desired (e.g., *White* can reflect origins in Europe, the
166 Middle East, or North Africa; *Asian* can reflect origins from areas ranging from India to
167 Japan). If more detailed characterizations of race or ethnicity are collected to enhance
168 data consistency, we recommend these characterizations be traceable to the five
169 minimum designations for race and two designations for ethnicity listed in numbers 3 and
170 4.
171
172
173
174
175
176
177

178 IV. CLINICAL TRIALS CONDUCTED OUTSIDE OF THE UNITED STATES

179
180 To assist in assessing the relevance of foreign study population data to United States populations,
181 we recommend sponsors use the OMB standardized categories when collecting data from study
182 participants in clinical trials conducted outside of the U.S. However, FDA recognizes that the

Contains Nonbinding Recommendations

Draft — Not for Implementation

183 recommended categories for race and ethnicity were developed in the United States and that
184 these categories may not adequately describe racial and ethnic groups in foreign countries.
185 Therefore, we recommend collecting the data using more detailed categories of race and
186 ethnicity to provide sponsors the flexibility to adequately characterize race and ethnicity for
187 studies conducted outside the United States. If sponsors choose to use more detailed
188 characterizations of race and ethnicity, it is important for analytical purposes that the data trace
189 back to the recommended categories described below.

- 190
- 191 1. For ethnicity, we recommend that collection of data in foreign countries follow the same
192 methods and designations used in the collection of data in U.S. clinical studies:
 - 193 • Hispanic or Latino
 - 194 • Not Hispanic or Latino
 - 195
 - 196 2. For racial designations in clinical studies conducted in foreign countries, we recommend that
197 the categories be modified to reflect the following as appropriate:
 - 198 • American Indian or Alaska Native
 - 199 • Asian
 - 200 • Black, of African heritage
 - 201 • Native Hawaiian or Other Pacific Islander
 - 202 • White

203

204 Note that the categories for inside and outside the US are very similar — only the description
205 of the Black designation varies from the OMB recommended categories.

Contains Nonbinding Recommendations

Draft — Not for Implementation

206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249

APPENDIX 1: HISTORY OF FEDERAL EFFORTS IN DATA COLLECTION ON RACE AND ETHNICITY AND OTHER SUBPOPULATIONS

During the past 20 or more years, a number of U.S. government initiatives have tried to address questions related to whether to and how to collect race and ethnicity data. Major initiatives are reviewed briefly here.

Office of Management and Budget (OMB) Initiatives

In May 1977, the OMB, issued “Statistical Policy Directive No. 15, Race and Ethnic Standards for Federal Statistics and Administrative Reporting.” The standards were developed in response to needs related to enforcing civil rights laws in education. These classifications were not to be interpreted as being scientific or anthropological in nature, nor viewed as determinants of eligibility for participation in any Federal program. They were developed in response to needs expressed by both the Executive Branch and the Congress to provide for the collection and use of compatible, non-duplicated, exchangeable race and ethnicity data by Federal agencies. This Directive specified four categorizations for race and two for ethnicity:

- American Indian or Alaskan Native
- Asian or Pacific Islander
- Black
- White

- Hispanic
- Not of Hispanic origin

The OMB Directive specified two questionnaire formats for data collection: (1) a format combining race and ethnicity and (2) a preferred format with two separate questions for race and ethnicity.

Since 1993, efforts have been under way to standardize the collection of race and ethnicity data to foster comparability across data collection and reporting systems. In 1997, revisions to OMB Directive 15, “Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity” (see appendix 2), were published. These revisions specified the minimum racial and ethnic diversity categories to be used when race and ethnicity are included in data collection and reporting for Federal programs. The Directive does not require that race and ethnicity be included in data collection and reporting, rather, it specifies what formats and categories to use when collecting this kind of data.

The revised OMB standards contain the following changes:

- Introduce the option to report more than one race for multiracial persons

Contains Nonbinding Recommendations

Draft — Not for Implementation

- 250 • Break the Asian or Pacific Islander category into two — one labeled Asian, the other
- 251 Native Hawaiian or Other Pacific Islander
- 252 • Change Hispanic to Hispanic or Latino
- 253 • Change Black to Black or African American
- 254 • Strongly encourage the use of self-identification
- 255 • Maintain the two question format for race and Hispanic ethnicity, when self-
- 256 identification is used (the Hispanic origin question should precede the race question)
- 257

258 The revised categorizations were described in an OMB guidance, *Implementation of the 1997*
259 *Standards for Federal Data on Race and Ethnicity* (2000), as sociopolitical and intended for use
260 in the collection of health data among other types of statistics.

261

Department of Health and Human Services Initiatives

262

263 In 1999, the Department of Health and Human Services (HHS) issued a report, *Improving the*
264 *Collection and Use of Racial and Ethnic Data in HHS*. The report describes HHS policy on
265 collecting and reporting data on race and ethnicity for HHS programs. The HHS report asks for
266 the inclusion of race and ethnicity categories in HHS-funded and -sponsored data collection and
267 reporting systems in all HHS programs, including in both health and human and social services.
268 This policy clearly states that the minimum standard categories in OMB Directive 15 and
269 revisions should be used when collecting and reporting data in HHS data systems or reporting
270 HHS-funded statistics. The policy was developed to (1) help monitor HHS programs, (2)
271 determine that Federal funds are being used in a nondiscriminatory manner, and (3) promote the
272 availability of standard race and ethnicity data across various agencies to facilitate HHS
273 responses to major health and human services issues.

274

National Institutes of Health Initiatives

275

276 In 1993, the National Institutes of Health (NIH) Revitalization Act directed the NIH to establish
277 guidelines for including women and minorities in NIH-sponsored clinical research. NIH was
278 directed to ensure that, when women and minorities were included as subjects, trials were
279 designed and carried out in a manner that would provide a valid analysis of any differences
280 between study subgroups, specifically women, minorities, and other participants in the trial.
281 NIH guidelines direct investigators to consider appropriate representation of subjects of different
282 genders and racial and ethnic backgrounds to provide the opportunity for detecting major
283 qualitative differences and to identify more subtle differences that may be explored more fully in
284 specifically targeted studies.

285

286 NIH guidelines established that prior to the design of phase 3 studies, there must be a review of
287 evidence to show whether clinically important gender and minority based differences are
288 expected. This evidence may include, but is not limited to, data derived from prior animal
289 studies, clinical observations, metabolic studies, genetic studies, pharmacology studies, and
290 observational, natural history, epidemiology, and other relevant studies. For example, if men and
291 women were thought to respond differently to an intervention, the phase 3 clinical trial must be
292 designed to answer two separate primary questions, one for men and the other for women, with
293

Contains Nonbinding Recommendations

Draft — Not for Implementation

295 adequate sample size for each. When prior studies neither support nor negate significant
296 differences of clinical or public health importance, the phase 3 trial will be required to support
297 the sufficient and appropriate accrual of participants by gender and race/ethnicity, so that a valid
298 analysis of the intervention effects can be performed. However, the trial is not required to
299 provide high statistical power for these comparisons. The term *valid analysis* refers generally to
300 a reasonable descriptive approach to the data.

301

Food and Drug Administration Initiatives

302

303 Beginning in the 1980s, FDA grew concerned about possible differences in drug safety and
304 efficacy among different population subgroups. Because the origins of subpopulation issues
305 stem from the identification of differences in response in women and geriatric populations,
306 references to those initiatives are included below. In 1983, the Agency initiated development of
307 guidance on the study of drugs to be used in geriatric patients. The guidance *Guideline for the*
308 *Study of Drugs Likely to be Used in the Elderly* was issued in 1989.

309

310 The first regulation specifying the analysis of population subsets appeared in 1985 in 21 CFR
311 314.50, which called for evidence to support the "dosage and administration section of the
312 labeling, including support for the dosage and dose interval recommended, and modifications for
313 specific subgroups (e.g., pediatrics, geriatrics, patients with renal failure..." 21 CFR
314 314.50(d)(5)).

315

316 In 1988, the Agency issued guidance describing elements of a New Drug Application's analysis
317 of clinical study data. The *Guideline for the Format and Content of the Clinical and Statistical*
318 *Sections of New Drug Applications* emphasized the importance of conducting subset analyses on
319 data from clinical studies submitted in New Drug Applications (NDAs). This guidance specified
320 race and ethnicity as types of population subsets for which separate analyses of data from clinical
321 studies should be conducted for assessments of product safety and effectiveness.

322

323 In July 1993, FDA published a guidance on the study of drugs in both genders entitled *Guideline*
324 *for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs*. The
325 guidance specifically called for analysis of trials by gender and for evaluating pharmacokinetics
326 in women. In the Federal Register notice announcing the guidance, FDA also abandoned the
327 policy explained in a 1977 guidance excluding women of childbearing potential from
328 participation in the earliest phases of clinical trials.

329

330 In 1993, FDA also published guidance on the Agency's use of the refusal-to-file (RTF) option if
331 certain analyses were not performed. The guidance states that the Agency can exercise its RTF
332 authority under 21 CFR 314.101(d)(3) if there is "inadequate evaluation for safety and/or
333 effectiveness of the population intended to use the drug, including pertinent subsets, such as
334 gender, age, and racial subsets."

335

336 In the Food and Drug Administration Modernization Act of 1997 (FDAMA), Congress directed
337 FDA to examine issues related to the inclusion of racial and ethnic groups in clinical trials of
338 new drugs. Section 115(b) of FDAMA required the Secretary, "in consultation with the Director
339

Contains Nonbinding Recommendations

Draft — Not for Implementation

340 of the National Institutes of Health and with representatives of the drug manufacturing industry,
341 [to] review and develop guidance, as appropriate, on the inclusion of women and minorities in
342 clinical trials...." (codified at 21 USC 355(b)(1)). In response, FDA established the FDAMA
343 Women and Minorities Working Group to review and implement this section of FDAMA. In a
344 report issued on July 20, 1998, the Working Group concluded that the Agency would implement
345 procedures to enhance its ability to gather and evaluate demographic data and then decide
346 whether additional guidance should be developed in the future.

347
348 In 1998, the Agency published the Demographic Rule, which amended the language in 21 CFR §
349 §312.33(a)(2) and 314.50(d)(5) requiring sponsors to tabulate the numbers of participants in
350 clinical trials by age group, gender, and race in investigational new drug application (IND)
351 annual reports and characterize the data in NDAs according to these same subgroups and, when
352 appropriate, present safety data from other subgroups of the population of patients, such as for
353 patients with renal failure or patients with different levels of severity of the disease.

354
355 In 1999, a guidance for industry entitled *Population Pharmacokinetics* made recommendations
356 on the use of population pharmacokinetics in the drug development process to help identify
357 differences in drug safety and efficacy among population subgroups, including race and
358 ethnicity. This guidance recommends that industry conduct clinical studies in subjects
359 representative of the population to be treated with the drug.

360
361 In 2000, the guidance *Content and Format of the Adverse Reactions Section of Labeling for*
362 *Human Prescription Drugs and Biologics* was issued to assist sponsors in developing the adverse
363 reactions section of labeling for human prescription drug and biological products. It
364 recommended presentation of relevant racial and ethnicity subgroup information on product
365 labeling.

366
367 The May 2001 guidance for industry *Clinical Studies Section of Labeling for Prescription Drugs*
368 *and Biologics — Content and Format* explains that the clinical studies section of the labeling
369 should include a summary statement about the results of the required explorations of treatment
370 effects in age, gender, and racial subgroups. In October 2001, a guidance for industry was issued
371 (*Content and Format for Geriatric Labeling*) that provides information on submitting geriatric
372 (persons aged 65 years or older) labeling for human prescription drugs and biological products.

373
374 In 2002 in the Best Pharmaceuticals for Children Act, the FDA was directed to monitor the racial
375 and ethnic designations of children participating in clinical studies for pharmaceutical products
376 (Pub. L. 107-109, Jan. 4, 2002).

ICH E5 - Guidance on Ethnic Factors in the Acceptability of Foreign Clinical Data

379
380 In 1999, as part of an international effort among Japan, the European Union, and the United
381 States to harmonize technical requirements for pharmaceutical drug development and regulation
382 (ICH), the FDA published a guidance entitled *E5 Guidance on Ethnic Factors in the*
383 *Acceptability of Foreign Clinical Data* to permit the clinical data collected in one region to be
384 used in the registration or approval of a drug or biological product in another region, while

Contains Nonbinding Recommendations

Draft — Not for Implementation

385 allowing for the influence of ethnic factors (63 FR 31790, June 10, 1999). The *E5* guidance
386 defines ethnic factors that affect response in terms of both intrinsic and extrinsic issues. Because
387 differences in ethnic factors have the potential to adversely affect some subpopulations, the *E5*
388 guidance provides a general framework for how to evaluate medicines with regard to their
389 sensitivity to ethnic factors.

Contains Nonbinding Recommendations

Draft — Not for Implementation

APPENDIX 2: REVISED DIRECTIVE 15

**OMB Standards for Maintaining, Collecting, and Presenting Federal Data
on Race and Ethnicity**

(Adopted on October 30, 1997)

This classification provides a minimum standard for maintaining, collecting, and presenting data on race and ethnicity for all Federal reporting purposes. The categories in this classification are social-political constructs and should not be interpreted as being scientific or anthropological in nature. They are not to be used as determinants of eligibility for participation in any Federal program. The standards have been developed to provide a common language for uniformity and comparability in the collection and use of data on race and ethnicity by Federal agencies.

The standards have five categories for data on race: American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, and White. There are two categories for data on ethnicity: "Hispanic or Latino," and "Not Hispanic or Latino."

1. Categories and Definitions

The minimum categories for data on race and ethnicity for Federal statistics, program administrative reporting, and civil rights compliance reporting are defined as follows:

-- **American Indian or Alaska Native.** A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment.

-- **Asian.** A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam.

-- **Black or African American.** A person having origins in any of the black racial groups of Africa. Terms such as "Haitian" or "Negro" can be used in addition to "Black or African American."

-- **Hispanic or Latino.** A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. The term, "Spanish origin," can be used in addition to "Hispanic or Latino."

-- **Native Hawaiian or Other Pacific Islander.** A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands.

-- **White.** A person having origins in any of the original peoples of Europe, the Middle East, or North Africa.

Respondents shall be offered the option of selecting one or more racial designations.

Recommended forms for the instruction accompanying the multiple response question are "Mark one or more" and "Select one or more."

2. Data Formats

The standards provide two formats that may be used for data on race and ethnicity. Self-reporting or self-identification using two separate questions is the preferred method for collecting data on

Contains Nonbinding Recommendations

Draft — Not for Implementation

435 race and ethnicity. In situations where self-reporting is not practicable or feasible, the combined
436 format may be used.

437
438 In no case shall the provisions of the standards be construed to limit the collection of data to the
439 categories described above. The collection of greater detail is encouraged; however, any
440 collection that uses more detail shall be organized in such a way that the additional categories
441 can be aggregated into these minimum categories for data on race and ethnicity.

442
443 With respect to tabulation, the procedures used by Federal agencies shall result in the production
444 of as much detailed information on race and ethnicity as possible. However, Federal agencies
445 shall not present data on detailed categories if doing so would compromise data quality or
446 confidentiality standards.

447 448 **a. Two-question format**

449
450 To provide flexibility and ensure data quality, separate questions shall be used wherever feasible
451 for reporting race and ethnicity. When race and ethnicity are collected separately, ethnicity shall
452 be collected first. If race and ethnicity are collected separately, the minimum designations are:

453 **Race:**

- 454 -- American Indian or Alaska Native
- 455 -- Asian
- 456 -- Black or African American
- 457 -- Native Hawaiian or Other Pacific Islander
- 458 -- White

459 **Ethnicity:**

- 460 -- Hispanic or Latino
- 461 -- Not Hispanic or Latino

462
463 When data on race and ethnicity are collected separately, provision shall be made to report the
464 number of respondents in each racial category who are Hispanic or Latino.
465 When aggregate data are presented, data producers shall provide the number of respondents who
466 marked (or selected) only one category, separately for each of the five racial categories. In
467 addition to these numbers, data producers are strongly encouraged to provide the detailed
468 distributions, including all possible combinations, of multiple responses to the race question. If
469 data on multiple responses are collapsed, at a minimum the total number of respondents
470 reporting "more than one race" shall be made available.

471 472 **b. Combined format**

473
474 The combined format may be used, if necessary, for observer-collected data on race and
475 ethnicity. Both race (including multiple responses) and ethnicity shall be collected when
476 appropriate and feasible, although the selection of one category in the combined format is
477 acceptable. If a combined format is used, there are six minimum categories:

- 478 -- American Indian or Alaska Native
- 479 -- Asian

Contains Nonbinding Recommendations

Draft — Not for Implementation

- 480 -- Black or African American
- 481 -- Hispanic or Latino
- 482 -- Native Hawaiian or Other Pacific Islander
- 483 -- White

484
485 When aggregate data are presented, data producers shall provide the number of respondents who
486 marked (or selected) only one category, separately for each of the six categories. In addition to
487 these numbers, data producers are strongly encouraged to provide the detailed distributions,
488 including all possible combinations, of multiple responses. In cases where data on multiple
489 responses are collapsed, the total number of respondents reporting "Hispanic or Latino and one
490 or more races" and the total number of respondents reporting "more than one race" (regardless of
491 ethnicity) shall be provided.

492 493 **3. Use of the Standards for Record Keeping and Reporting**

494
495 The minimum standard categories shall be used for reporting as follows:

496 497 **a. Statistical reporting**

498
499 These standards shall be used at a minimum for all federally sponsored statistical data collections
500 that include data on race and/or ethnicity, except when the collection involves a sample of such
501 size that the data on the smaller categories would be unreliable, or when the collection effort
502 focuses on a specific racial or ethnic group. Any other variation will have to be specifically
503 authorized by the OMB through the information collection clearance process. In those cases
504 where the data collection is not subject to the information collection clearance process, a direct
505 request for a variance shall be made to OMB.

506 507 **b. General program administrative and grant reporting**

508
509 These standards shall be used for all Federal administrative reporting or record keeping
510 requirements that include data on race and ethnicity. Agencies that cannot follow these standards
511 must request a variance from OMB. Variances will be considered if the agency can demonstrate
512 that it is not reasonable for the primary reporter to determine racial or ethnic background in terms
513 of the specified categories, that determination of racial or ethnic background is not critical to the
514 administration of the program in question, or that the specific program is directed to only one or
515 a limited number of racial or ethnic groups.

516 517 **c. Civil rights and other compliance reporting**

518
519 These standards shall be used by all Federal agencies in either the separate or combined format
520 for civil rights and other compliance reporting from the public and private sectors and all levels
521 of government. Any variation requiring less detailed data or data which cannot be aggregated
522 into the basic categories must be specifically approved by OMB for executive agencies. More
523 detailed reporting which can be aggregated to the basic categories may be used at the agencies'
524 discretion.

Contains Nonbinding Recommendations

Draft — Not for Implementation

525

4. Presentation of Data on Race and Ethnicity

527

528 Displays of statistical, administrative, and compliance data on race and ethnicity shall use the
529 categories listed above. The term "nonwhite" is not acceptable for use in the presentation of
530 Federal Government data. It shall not be used in any publication or in the text of any report.
531 In cases where the standard categories are considered inappropriate for presentation of data on
532 particular programs or for particular regional areas, the sponsoring agency may use:

533

534 a. The designations "Black or African American and Other Races" or "All Other Races" as
535 collective descriptions of minority races when the most summary distinction between the
536 majority and minority races is appropriate;

537

538 b. The designations "White," "Black or African American," and "All Other Races" when the
539 distinction among the majority race, the principal minority race, and other races is appropriate; or

540

541 c. The designation of a particular minority race or races, and the inclusion of "Whites" with "All
542 Other Races" when such a collective description is appropriate. In displaying detailed
543 information that represents a combination of race and ethnicity, the description of the data being
544 displayed shall clearly indicate that both bases of classification are being used.

545

546 When the primary focus of a report is on two or more specific identifiable groups in the
547 population, one or more of which is racial or ethnic, it is acceptable to display data for each of
548 the particular groups separately and to describe data relating to the remainder of the population
549 by an appropriate collective description.

550

5. Effective Date

552

553 The provisions of these standards are effective immediately for all new and revised record
554 keeping or reporting requirements that include racial and/or ethnic information. All existing
555 record keeping or reporting requirements shall be made consistent with these standards at the
556 time they are submitted for extension, or not later than January 1, 2003.

Contains Nonbinding Recommendations

Draft — Not for Implementation

REFERENCES

- 557
558
559
- 560 Exner, D., D. Dries, M. Donamski, and J. Cohn, 2001, "Lesser Response to Angiotensin-
561 Converting-Enzyme Inhibitor Therapy in Black as Compared with White Patients with
562 Left Ventricular Dysfunction," *N Engl J Med*, 344: 1351-1357.
- 563 McHutchison, J., T. Poynard, S. Pianko, S. Gordon, A. Reid, et. al., 2000, "The Impact of
564 Interferon Alpha Plus Ribavirin on Response to Therapy in Black Patients with Chronic
565 Hepatitis C. The International Hepatitis Interventional Therapy Group,"
566 *Gastroenterology*, 119: 1317-23.
- 567 Reddy, K. R., J. Hoofnagle, M. Tong, W. Lee, P. Pockros, et al., 1999, "Racial Differences in
568 Responses to Therapy with Interferon in Chronic Hepatitis C. Consensus Interferon
569 Study Group." *Hepatology*, 30: 787-93.
- 570 Taylor, S., 2002, "Skin of Color: Biology, Structure, Function, and Implications for
571 Dermatologic Disease," *Journal of American Academy of Dermatology*, 46:S41-62.
- 572 Xie, H., R. Kim, A. Wood, and C. Stein, 2001, "Molecular Basis of Ethnic Differences in Drug
573 Disposition and Response," *Annu Rev Pharmacol Toxicol*; 41:815-50.
- 574 Yancy, A., M. Fowler, W. Colucci, E. Gilbert, M. Bristow, et. al., 2001 "Race and the Response
575 to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure," *N Engl J*
576 *Med*, 344: 1358-1365.

Contains Nonbinding Recommendations

Draft — Not for Implementation

577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613

BIBLIOGRAPHY

DHHS Policy and Reports

Department of Health and Human Services (DHHS), 1997, *Policy For Improving Race and Ethnicity Data*, October 24, 1997, <http://www.hhs.gov/oirm/infocollect/nclusion.html>.

DHHS, 1999, *Improving the Collection and Use of Racial and Ethnic Data in HHS*, joint report of the HHS Data Council Working Group on Racial and Ethnic Data and the Data Work Group of the HHS Initiative to Eliminate Racial and Ethnic Disparities in Health, December 1999, <http://aspe.hhs.gov/datacncl/racerpt/index.htm>.

FDA Regulations

Food and Drug Administration (FDA), 1998, "Investigational New Drug Applications and New Drug Applications," Final Rule, *Federal Register*, Vol. 63 p. 6854, February 11, 1998.

FDA, *Content and Format for Human Prescription Drugs; Addition of "Geriatric Use" Subsection in the Labeling*, Final Rule, *Federal Register*, Vol. 62, p. 45313, August 27, 1997.

FDA Guidance for Industry

FDA, *Clinical Studies Section of Labeling for Prescription Drugs and Biologics*, July 2001.

FDA, *Content and Format for Geriatric Labeling*, October 2001. FDA, *Content and Format of the Adverse Reactions Section of Labeling for Human Prescription Drugs and Biologics* (draft), June 2000.

FDA, *General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products* (draft), November 1998.

FDA, *General Considerations for the Clinical Evaluation of Drugs*, 1977.

FDA, *Format and Content of the Clinical and Statistical Sections of an Application*, July 1988.

FDA, *Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs*, July 1993.

FDA, *Study of Drugs Likely to be Used in the Elderly*, November 1989.

FDA, *In Vivo Drug Metabolism/Drug Interaction Studies: Study Design, Data Analysis, and Recommendations for Dosing and Labeling*, November 1999.

FDA, *Pharmacokinetics in Patients with Hepatic Insufficiency: Study Design, Data Analysis, and Impact on Dosing and Labeling* (draft), December 7, 1999.

FDA, *Pharmacokinetics in Patients with Impaired Renal Function: Study Design, Data Analysis and Impact on Dosing and Labeling*, May 1998.

FDA, *Population Pharmacokinetics*, February 1999.

FDA, *Refusal to File*, July 12, 1993.

Contains Nonbinding Recommendations

Draft — Not for Implementation

614

615 ICH Guidances

616 International Conference on Harmonisation (ICH), 2000, *E11 Clinical Investigation of Medicinal*
617 *Products in the Pediatric Population*, ICH, December 2000.

618 ICH, *E4 Dose Response Information to Support Drug Registration*, ICH, November 1994.

619 ICH, *E7 Studies in Support of Special Populations: Geriatrics*, ICH, August 1994.

620 ICH, *E5 Ethnic Factors in the Acceptability Of Foreign Data*, ICH, June 1998.

621

622 Other Sources

623 Office of Management and Budget, 1994, Standards for the Classification of Federal Data on
624 Race and Ethnicity, http://www.whitehouse.gov/omb/fedreg/notice_15.html.

625 General Accounting Office, *FDA Needs to Ensure More Study of Gender Differences in*
626 *Prescription Drug Testing*, GAO/HFD-93-17.

627 NIH Revitalization Act of 1993, (PL 103-43).

628 NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research-

629 Updated August 1, 2000. available at

630 http://grants.nih.gov/grants/funding/women_min/women_min.htm.

631 Food and Drug Administration Modernization Act of 1997 (FDAMA) (P.L. 105-115).

632 Best Pharmaceuticals Act for Children of 2002 (P.L.107-109).

633